

Supporting Information


Design and Synthesis of New 4-(3,4,5-Trimethoxyphenyl) Thiazole–Pyrimidine Derivatives as Potential Antiproliferative Agents


Ashraf K. El-Damasy ^{1,2,†}, Heewon Jin ^{1,†}, Mohamed A. Sabry ², Hyun Ji Kim ¹,
Mohammed M. Alanazi ³, Seon Hee Seo ⁴, Eun-Kyoung Bang ¹ and Gyochang Keum ^{1,5,*}

1. Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; ph_karem2000@mans.edu.eg (A.K.E.-D.); hwjin37@snu.ac.kr (H.J.); hjkim926@kist.re.kr (H.J.K.); eunkbang@kist.re.kr (E.-K.B.)
 2. Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt; midoegy1992@hotmail.com
 3. Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; mmalanazi@ksu.edu.sa
 4. Center for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea; shseo@kist.re.kr
 5. Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology (UST), Seoul 02792, Republic of Korea
- * Correspondence: gkeum@kist.re.kr
† These authors contributed equally to the work.


Contents	Pages
Figure S1. ¹ H NMR and ¹³ C NMR spectra.	2–18
Figure S2. HRMS charts.	19–33
Figure S3. HPLC chromatograms.	34–37
Figure S4. NCI-60 cell line screening results.	38–41

Figure S1. ^1H NMR and ^{13}C NMR spectra.







JHW-VII-55




JHW-VII-55






3


AKA-V-187-NaH



AKA-V-187-NaH




4





4a

JHW-6-47




AKA-VI-29






4b


AKA-VI-29






4c


AKA-VI-27






4d


AKA-VI-33






4e


JHW-6-37







4f

AKA-VI-35







AKA-VI-43




AKA-VI-43







4h

AKA-VI-41




AKA-VI-41






4i


JHW-VI-49_2020







4j


JHW-TMP-Pyd-EtOH_2020_af.cc



JHW-TMP-Ph-EtOH_2020









4l


AKA-VI-31






4m


AKA-VI-25-after column





4n

AKA-VI-23-check for proton



AKA-VI-23-check for carbon







Figure S2. HRMS charts.




3







Mass Spectrum: JHW-I-20 (Positive mode)







Mass Spectrum: JHW-I-7 (Positive mode)







Mass Spectrum: JHW-I-2 (Positive mode)







Mass Spectrum: JHW-I-10 (Positive mode)






Mass Spectrum: JHW-I-12 (Positive mode)







4f


Mass Spectrum: JHW-I-11 (Positive mode)






Mass Spectrum: JHW-I-18 (Positive mode)







4h


Mass Spectrum: JHW-I-8 (Positive mode)







Mass Spectrum: JHW-I-22 (Positive mode)






Mass Spectrum: JHW-I-19 (Positive mode)







4k


Mass Spectrum: JHW-I-101 (Positive mode)






Mass Spectrum: JHW-I-6 (Positive mode)






4m

Mass Spectrum: JHW-I-0 (Positive mode)





4n

Mass Spectrum: JHW-I-102 (Positive mode)






Figure S3. HPLC chromatograms.

4a




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.035	MM	0.0577	457.36737	132.04756	2.7660
2	8.196	MM	0.0832	1.57902e4	3164.52417	95.4942
3	8.529	MM	0.0661	63.35807	15.98133	0.3832
4	8.853	MM	0.0624	130.91321	34.96431	0.7917
5	9.083	MM	0.0629	93.40739	24.75652	0.5649

4b




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.363	MM	0.0579	104.45980	30.07361	0.6206
2	6.784	MM	0.0617	105.35685	28.43876	0.6260
3	7.172	MM	0.1036	201.37787	32.40592	1.1964
4	7.912	MM	0.0880	1.59298e4	3017.06812	94.6430
5	8.528	MM	0.0591	133.52155	37.67151	0.7933
6	8.786	MM	0.0581	356.94733	102.36401	2.1207

4c




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.441	MM	0.0531	16.21639	5.09241	0.1000
2	9.943	MM	0.0861	1.56719e4	3035.16284	96.6872
3	10.303	MM	0.0711	240.45490	56.35232	1.4835
4	10.774	MM	0.0697	280.30371	67.05331	1.7293

4d




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.514	MM	0.0753	77.76376	17.22113	0.3557
2	11.252	MM	0.0665	216.86659	54.37672	0.9920
3	11.554	MM	0.1083	2.11809e4	3259.49268	96.8853
4	11.945	MM	0.1191	256.63257	35.92110	1.1739
5	12.460	MM	0.0647	129.67278	33.39864	0.5931

4e



4f








4g**4h**

Figure S4. NCI-60 cell line screening results.





4b







4c





4k





4n

